Abstract
Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
Current Diabetes Reviews
Title: Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA
Volume: 3 Issue: 3
Author(s): Scott D. Doughman, Srirama Krupanidhi and Carani B. Sanjeevi
Affiliation:
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
Abstract: Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Export Options
About this article
Cite this article as:
Scott D. Doughman , Srirama Krupanidhi and Carani B. Sanjeevi , Omega-3 Fatty Acids for Nutrition and Medicine: Considering Microalgae Oil as a Vegetarian Source of EPA and DHA, Current Diabetes Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339907781368968
DOI https://dx.doi.org/10.2174/157339907781368968 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Trials: How to Assess Confounding and Why So
Current Clinical Pharmacology Lifestyle, Maternal Nutrition and Healthy Pregnancy
Current Vascular Pharmacology Novel Plant Sterol and Stanol Derivatives with Beneficial Properties:Efficacy and Safety
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Editorial (Thematic Issue: Biochemical Targets and Biomarkers for Central Nervous System Protection and Monitoring)
CNS & Neurological Disorders - Drug Targets Antitubercular and Antimicrobial Activity of NH4VO3 Promoted 1,4- Dihydropyridine Incorporated 1,3,4-trisubstituted Pyrazole
Letters in Drug Design & Discovery Dietary Factors and Hyperuricaemia
Current Pharmaceutical Design Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients
Current Medicinal Chemistry Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Optimization and Assay of Antioxidant Potential of Two Penicillium spp. by Different Procedures
Current Biotechnology To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Editorial: Vascular Risk Estimation by Specialist Nurses
Current Vascular Pharmacology Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Recent Advances in the Discovery and Development of Direct Coagulation Factor Xa Inhibitors
Current Pharmaceutical Design Frailty Among Alzheimer’s Disease Patients
CNS & Neurological Disorders - Drug Targets Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates
Current Pharmaceutical Design Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design New Targets for Anticoagulation and Future Perspectives
Current Drug Discovery Technologies